

Author Index for Volume 19

- Abboud M, 110
Aboulker J-P, 233
Adams RJ, 110
Anderson CB, 188
Anderson S, 249
Applegate W, 314
ARNS 005/ACTG 154
 Trial Group, 233
Ashley P, 419
Aubertin J, 233
Azen SP, 217
- Baird-Cox KA, 451
Baisden CE, 419
Baker D, 546
Barton FB, 477
Bass DC, 499
Berkowitz K, 217
Berman B, 110
Bigger JT Jr, 1
Bittner V, 391
Black HR, 370
Blank J, 25
Blot WJ, 352
Boggs SR, 297
Boudes Pol, 257
Bowen D, 461, 606
Brambilla D, 110
Briançon S, 336
Brown LM, 352
Bryant J, 577
Buchanan TA, 217
Bush T, 314
Bycott PW, 557
Bzoch KR, 297
- Capelozza Filho L, 297
Carl E, 110
Chan W, 391
Chang Y-S, 352
Charreau I, 233
Chêne G, 233
Chuang-Stein C, 167
Connett JE, 525
Connor PB, 39
CONVINCE Research
 Group, 370
Cool VA, 451
Cummings C, 419
- Cure J, 110
- Dailey M, 606
Davis CE, 477
Davis CS, 178
Day S, 15
de Souza Freitas JA, 297
de Souza TV, 297
Demakis J, 134
Dequae L, 233
Deupree RH, 404
Deykin D, 134
Diener-West M, 39
Dignam JJ, 577
Dixon-Wood V, 297
Donfield SM, 451
Driscoll C, 110
Dulberg E, 391
Dupont WD, 591
- Egan DA, 1
Eghtesady P, 198
Ellenberg SS, 530
Elliott WJ, 370
Erbland ML, 404
Espeland MA, 606
- Fairweather WR, 477
Fakouhi TD, 370
Favier A, 336
Fayers P, 15
Feldman HA, 391
Feniman MB, 297
Fihn SD, 134
Files B, 110
Fisher B, 577
Fouad M, 461
Fraumeni JF Jr, 352
Friedman L, 523
Furberg C, 314
- Gail MH, 352
Galan P, 336
Gallagher D, 110
Garla LA, 297
Gent M, 535
George SL, 477
George V, 461
Gergen P, 546
- Glass A, 25
Goff DC, 391
Goldgerg IA, 451
Goyal N, 159
Graciano MI, 297
Grady D, 314
Grambsch P, 370
Grandits G, 370
Green SB, 427
Grimm RH Jr, 370
Groves FD, 352
Guedes de Azevedo Bento
 Gonçalves C, 297
- Hafner R, 233
Hagner S, 110
Hansson L, 370
Harland R, 159
Harvey D, 15
Hauck WW, 249
Hawk SM, 451
Hawkins BS, 39
Heinrich JP, 352
Hemophilia Growth and
 Development
 Study, 451
Hemsell DL, 499
Henderson WG, 134
Hendrix SL, 499
Hercberg S, 336
Herndon JE II, 440
HERS Research Group,
 314
Hillis A, 419
Hoel LN, 451
Holley RL, 499
Honohan T, 477
Hornberger J, 198
Hsu L, 110
Hu J, 352
Hu W, 56
Hulley SB, 314
Hurlet A, 110
- IONDT Research Group,
 276
- James KE, 131
Jin M-L, 352

- Jones BN, 606
 Jorge JC, 297
 Joseph C, 546

 Karrison TG, 430
 Kelsey SF, 499
 Kemker J, 297
 Kjos S, 217
 Knatterud GL, 477, 537
 Kupfer C, 539
 Kutlar A, 110

 Lachenbruch PA, 571
 Lacoucière Y, 370
 Lave JR, 499
 Lazarini Marques I, 297
 Leber PD, 178
 Lenfant C, 523
 Leport C, 233
 Levin B, 1
 Lewin J, 110
 Lewis CE, 461
 Li J-Y, 352
 Liu W-D, 352
 Luft B, 233

 Ma J-L, 352
 Machado Neto JS, 297
 Maeder MA, 451
 Mahoney EM, 451
 Malvy D, 336
 Manheim LM, 149
 Mann NC, 391
 Marcus SM, 249
 Mark SD, 352
 Marks R, 297
 McBee WL, 606
 McGovern PG, 391
 McKie VC, 110
 McNiff Mortimer K, 546
 Meier P, 1
 Meinert CL, 515, 541
 Menezes Cardoso
 Martinelli AP, 297
 Miller S, 110
 Mitchell H, 546
 Montagnoli LC, 297
 Morlat P, 233
 Morwey R, 477
 Muller J, 370
 Muniz Pimentel
 Chinellato MC,
 297
 Murray DM, 391

 Nackashi AJ, 297
 Neaton JD, 370, 525
 Ness RB, 499
 Neuhauser DB, 427
 Newhouse MM, 39
 Nichols FT, 110
 Niewoehner DE, 404
 Nova Silva ML, 297

 O'Neill R, 477
 Ober C, 430
 Oddone E, 134
 Olivieri N, 110
 Overall JE, 188

 Parides MK, 1
 PEACH Study
 Investigators, 499
 Pearson SK, 451
 Pegelow C, 110
 Pegoraro-Krook MI, 297
 Peipert J, 499
 Pereira Lauris JR, 297
 Peters RK, 217
 Piazentin SH, 297
 Plummer WD, 591
 Porter V, 461
 Preziosi P, 336
 Prouschan MA, 391

 Rabkin CS, 352
 Rajab MH, 419
 Randall H, 499
 Rapp SR, 606
 REACT Study Group, 391
 Reboussin BA, 606
 Rees R, 159
 Richard SK, 451
 Riggs B, 314
 Roach S, 110
 Rockhold FW, 477
 Rolnitsky LM, 1
 Roussel A-M, 336

 Salamon R, 233
 SCCOPE Study Group,
 404
 Scher C, 110
 Seagle MB, 297
 Senturia YD, 546
 Shobaki G, 188
 Shumaker SA, 606
 Shuster JJ, 269

 Sirois PA, 451
 Sleight P, 370
 Sondheiner SJ, 499
 Songer TJ, 499
 Soper DE, 499
 Stylianou M, 391
 Sweet RL, 499

 Taylor JMG, 557
 Terrell T, 606
 Tighe F, 110
 Triol I, 336
 TRIPOD Study Group, 217

 Urban N, 461

 Valanis B, 25
 Veatch RM, 533
 Vichinsky E, 110
 Vickers A, 159
 Vildé J-L, 233
 Villamaria FJ, 419

 Wacławiw MA, 110
 Wang W, 110
 Weber MA, 370
 Wedner HJ, 546
 Weinberger M, 134
 Weinmann G, 523
 Wharton W, 297
 WHIMS Investigators, 606
 White WB, 370
 WHT:FSMP Investigators
 Group, 461
 Wieand HS, 577
 Williams G, 370
 Williams WN, 297
 Wittes J, 313, 370
 Wolmark N, 577
 Women's Health Initiative
 Study Group, 61
 Woods G, 110
 Wright E, 110

 Xiang A, 217
 Xu G-W, 352

 You W-C, 352

 Zanchetti A, 370
 Zhang J, 56
 Zhang L, 352
 Zimmerman MC, 297
 Zimmerman RA, 110

Subject Index for Volume 19

ACTG PROTOCOL 019

An Evaluation of a Measure of the Proportion of the Treatment Effect Explained by a Surrogate Marker, 557

ACUPUNCTURE

Do Certain Countries Produce Only Positive Results? A Systematic Review of Controlled Trials, 159

ADNEXITIS

Design of a PID Evaluation and Clinical Health (PEACH) Study, 499

AGE AT SURGERY

A Methodology Report of a Randomized Prospective Clinical Trial to Assess Velopharyngeal Function for Speech Following Palatal Surgery, 297

AGING

The Women's Health Initiative Memory Study (WHIMS): A Trial of the Effect of Estrogen Therapy in Preventing and Slowing the Progress of Dementia, 606

ALZHEIMER'S DISEASE

The Women's Health Initiative Memory Study (WHIMS): A Trial of the Effect of Estrogen Therapy in Preventing and Slowing the Progress of Dementia, 606

ANTIOXIDANTS

A Primary Prevention Trial Using Nutritional Doses of Antioxidant Vitamins and Minerals in Cardiovascular Diseases and Cancers in a General Population: The SU.VI.MAX Study-Design, Methods, and Participant Characteristics, 336

ARRHYTHMIA

Changes in Sample Size and Length of Follow-up to Maintain Power in The Coronary Artery Bypass Graft (CABG) Patch Trial, 1

ASCORBIC ACID

Factorial Trial of Three Interventions to Reduce the Progression of Precancerous Gastric Lesions in Shandong, China: Design Issues and Initial Data, 352

ATENOLOL

Rationale and Design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial, 370

AUDITING

Guidelines for Quality Assurance in Multicenter Trials: A Position Paper, 477

BAYESIAN METHODS

Bayesian Biostatistics (book review), 271
Early Stopping of a Clinical Trial When There is Evidence of No Treatment Benefit: Protocol B14 of the National Surgical Adjuvant Breast and Bowel Project, 577

BINOMIAL MODELS

Single or Double Data Entry: Considerations Based on a Simple Binomial Model (letter), 56

BIOSTATISTICS

Bayesian Biostatistics (book review), 271

BREAST CANCER

Early Stopping of a Clinical Trial When There is Evidence of No Treatment Benefit: Protocol B14 of the National Surgical Adjuvant Breast and Bowel Project, 577

**CALCIUM AND VITAMIN D
SUPPLEMENTATION**

Design of the Women's Health Initiative
Clinical Trial and Observational
Study, 61

CALCIUM ANTAGONISTS

Rationale and Design for the Controlled
ONset Verapamil INvestigation of
Cardiovascular Endpoints
(CONVINCE) Trial, 370

CANCER

A Design Alternative for Two-Stage,
Phase II, Multicenter Cancer
Clinical Trials, 440

A Primary Prevention Trial Using
Nutritional Doses of Antioxidant
Vitamins and Minerals in
Cardiovascular Diseases and
Cancers in a General Population:
The SU.VI.MAX Study-Design,
Methods, and Participant
Characteristics, 336

Early Stopping of a Clinical Trial When
There is Evidence of No
Treatment Benefit: Protocol B14 of
the National Surgical Adjuvant
Breast and Bowel Project, 577

Recruitment Strategies in the Women's
Health Trial: Feasibility Study in
Minority Populations, 461

CARDIOVASCULAR DISEASES

A Primary Prevention Trial Using
Nutritional Doses of Antioxidant
Vitamins and Minerals in
Cardiovascular Diseases and
Cancers in a General Population:
The SU.VI.MAX Study-Design,
Methods, and Participant
Characteristics, 336

Recruitment Strategies in the Women's
Health Trial: Feasibility Study in
Minority Populations, 461

CARRY-OVER EFFECT

Threats to the Validity of Clinical Trials
Employing Enrichment
Strategies for Sample Selection,
178

CD4 T CELLS

An Evaluation of a Measure of the
Proportion of the Treatment
Effect Explained by a Surrogate
Marker, 557

Comparability of Absolute/Percent
CD4+ T-Lymphocytes
Completed Locally and
Centrally, 451

CENTRAL LABORATORY

Comparability of Absolute/Percent
CD4+ T-Lymphocytes
Completed Locally and
Centrally, 451

CEREBRAL HEMORRHAGE

Stroke Prevention Trial in Sickle Cell
Anemia, 110

CHILDREN/PEDIATRIC

Stroke Prevention Trial in Sickle Cell
Anemia, 110

Successful Techniques for Retention of
Study Participants in an Inner-
City Population, 546

**CHRONIC OBSTRUCTIVE
PULMONARY DISEASE**

Systemic Corticosteroids in Chronic
Obstructive Pulmonary Disease
Exacerbations (SCCOPE):
Rationale and Design of an
Equivalence Trial, 404

CIRCADIAN VARIATION

Rationale and Design for the Controlled
ONset Verapamil INvestigation
of Cardiovascular Endpoints
(CONVINCE) Trial,
370

CLEFT LIP AND PALATE

A Methodology Report of a Randomized
Prospective Clinical Trial to
Assess Velopharyngeal Function
for Speech Following Palatal
Surgery, 297

CLINICAL RESEARCH

Efficient Clinical Research (editorial), 427

COGNITIVE IMPAIRMENT

The Women's Health Initiative Memory
Study (WHIMS): A Trial of the
Effect of Estrogen Therapy in
Preventing and Slowing the
Progress of Dementia, 606

COHORT STUDY

Design of the Women's Health Initiative Clinical Trial and Observational Study, 61

Successful Techniques for Retention of Study Participants in an Inner-City Population, 546

COMMUNITY TRIAL DESIGN

Statistical Design of REACT (Rapid Early Action for Coronary Treatment), A Multisite Community Trial with Continual Data Collection, 391

COMPLIANCE

Drug Compliance in Therapeutic Trials: A Review, 257

CORONARY ARTERY BYPASS SURGERY

Changes in Sample Size and Length of Follow-up to Maintain Power in The Coronary Artery Bypass Graft (CABG) Patch Trial, 1

CORONARY HEART DISEASE

Heart and Estrogen/Progestin Replacement Study (HERS): Design, Methods, and Baseline Characteristics, 314

CORTICOSTEROIDS

Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease Exacerbations (SCCOPE): Rationale and Design of an Equivalence Trial, 404

COST EFFECTIVENESS

Cost-effectiveness in Health and Medicine (book review), 214

Health Services Research Clinical Trials: Issues in the Evaluation of Economic Costs and Benefits, 149

The Cost-Benefit of a Randomized Trial to a Health Care Organization, 198

COST EVALUATION

Health Services Clinical Trials: Design, Conduct, and Cost Methodology, 131

Health Services Research Clinical Trials: Issues in the Evaluation of Economic Costs and Benefits, 149

COX REGRESSION

Should We Adjust for Covariates in Nonlinear Regression Analyses of Randomized Trials, 249

An Evaluation of a Measure of the Proportion of the Treatment Effect Explained by a Surrogate Marker, 557

DATA INTEGRITY

Guidelines for Quality Assurance in Multicenter Trials: A Position Paper, 477

DATA MANAGEMENT

Double Data Entry: What Value, What Price?, 15

DATA MONITORING

Early Stopping of a Clinical Trial When There is Evidence of No Treatment Benefit: Protocol B14 of the National Surgical Adjuvant Breast and Bowel Project, 577

DATA VERIFICATION

Double Data Entry: What Value, What Price?, 15

Feasibility of Keying Data from Screen-Displayed Facsimile Images in an Ongoing Trial: The Collaborative Ocular Melanoma Study, 39

DECISION ANALYSIS

Prevention Effectiveness: Guide to Decision Analysis and Economic Evaluation (book review), 212

The Cost-Benefit of a Randomized Trial to a Health Care Organization, 198

DEMENTIA

The Women's Health Initiative Memory Study (WHIMS): A Trial of the Effect of Estrogen Therapy in Preventing and Slowing the Progress of Dementia, 606

DESIGN OF CLINICAL TRIALS

A Design Alternative for Two-Stage, Phase II, Multicenter Cancer Clinical Trials, 440

A Methodology Report of a Randomized Prospective Clinical Trial to Assess Velopharyngeal Function

- for Speech Following Palatal Surgery, 297
- A Primary Prevention Trial Using Nutritional Doses of Antioxidant Vitamins and Minerals in Cardiovascular Diseases and Cancers in a General Population: The SU.VI.MAX Study-Design, Methods, and Participant Characteristics, 336
- Cooperative Studies in Health Services Research in the Department of Veterans Affairs, 134
- Design of a PID Evaluation and Clinical Health (PEACH) Study, 499
- Design of the Women's Health Initiative Clinical Trial and Observational Study, 61
- Factorial Trial of Three Interventions to Reduce the Progression of Precancerous Gastric Lesions in Shandong, China: Design Issues and Initial Data, 352
- Heart and Estrogen/Progestin Replacement Study (HERS): Design, Methods, and Baseline Characteristics, 314
- Rationale and Design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial, 370
- Statistical Design of REACT (Rapid Early Action for Coronary Treatment), A Multisite Community Trial with Continual Data Collection, 391
- Stroke Prevention Trial in Sickle Cell Anemia, 110
- Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease Exacerbations (SCCOPE): Rationale and Design of an Equivalence Trial, 404
- The Design and Analysis of Sequential Clinical Trials* (book review), 604
- The Ischemic Optic Neuropathy Decompression Trial: (IONDT): Design and Methods, 276
- TRIPOD (TROglitazone in the Prevention of Diabetes): A Randomized, Placebo-controlled Trial of Troglitazone in Women With Prior Gestational Diabetes Mellitus, 217
- DIABETES**
- TRIPOD (TROglitazone in the Prevention of Diabetes): A Randomized, Placebo-controlled Trial of

Troglitazone in Women With Prior Gestational Diabetes Mellitus, 217

DIETARY MODIFICATION

Design of the Women's Health Initiative Clinical Trial and Observational Study, 61

DISEASE PREVENTION

Design of the Women's Health Initiative Clinical Trial and Observational Study, 61

DOUBLE DATA ENTRY

Double Data Entry: What Value, What Price?, 15

Feasibility of Keying Data from Screen-Displayed Facsimile Images in an Ongoing Trial: The Collaborative Ocular Melanoma Study, 39

Single or Double Data Entry: Considerations Based on a Simple Binomial Model (letter), 56

DRUG DEVELOPMENT

Drug Compliance in Therapeutic Trials: A Review, 257

Statistical Issues in Drug Development (book review), 494

ECONOMIC EVALUATION

Prevention Effectiveness: Guide to Decision Analysis and Economic Evaluation (book review), 212

EFFECTIVENESS STUDIES

Three Years of Experience with Prospective Randomized Effectiveness Studies, 419

EMERGENCY MEDICINE

Statistical Design of REACT (Rapid Early Action for Coronary Treatment), A Multisite Community Trial with Continual Data Collection, 391

ENRICHMENT DESIGN

Threats to the Validity of Clinical Trials Employing Enrichment Strategies for Sample Selection, 178

EQUIVALENCE TRIAL

Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease

Exacerbations (SCCOPE):
Rationale and Design of an
Equivalence Trial, 404

ESTROGEN

Heart and Estrogen/Progestin
Replacement Study (HERS):
Design, Methods, and Baseline
Characteristics, 314
The Women's Health Initiative Memory
Study (WHIMS): A Trial of the
Effect of Estrogen Therapy in
Preventing and Slowing the
Progress of Dementia, 606

ETHNICITY

Recruitment Strategies in the Women's
Health Trial: Feasibility Study in
Minority Populations, 461

EXTERNAL COMPARISONS

Publishing Clinical Trials and Dealing
with External Comparisons
(editorial), 269

EXTERNAL VALIDITY

Threats to the Validity of Clinical Trials
Employing Enrichment
Strategies for Sample Selection,
178

FACTORIAL INTERVENTION STUDIES

Factorial Trial of Three Interventions to
Reduce the Progression of
Precancerous Gastric Lesions in
Shandong, China: Design Issues
and Initial Data, 352

FREQUENCY OF MEASUREMENTS

Comparative Evaluations of Two Models
for Estimating Sample Sizes for
Tests on Trends Across Repeated
Measurements, 188

FURLOW

A Methodology Report of a Randomized
Prospective Clinical Trial to
Assess Velopharyngeal Function
for Speech Following Palatal
Surgery, 297

GARLIC

Factorial Trial of Three Interventions to
Reduce the Progression of
Precancerous Gastric Lesions in

Shandong, China: Design Issues
and Initial Data, 352

GROUP SEQUENTIAL MONITORING

Changes in Sample Size and Length of
Follow-up to Maintain Power in
The Coronary Artery Bypass Graft
(CABG) Patch Trial, 1

HEALTH PROMOTION

Statistical Design of REACT (Rapid Early
Action for Coronary Treatment),
A Multisite Community Trial with
Continual Data Collection, 391

HEALTH SERVICES RESEARCH

Cooperative Studies in Health Services
Research in the Department of
Veterans Affairs, 134
Health Services Clinical Trials: Design,
Conduct, and Cost
Methodology, 131
Health Services Research Clinical Trials:
Issues in the Evaluation of
Economic Costs and Benefits, 149

HEALTH-CARE DELIVERY

Cooperative Studies in Health Services
Research in the Department of
Veterans Affairs, 134

HEALTH-CARE ORGANIZATION

Cooperative Studies in Health Services
Research in the Department of
Veterans Affairs, 134

HELICOBACTER PYLORI

Factorial Trial of Three Interventions to
Reduce the Progression of
Precancerous Gastric Lesions in
Shandong, China: Design Issues
and Initial Data, 352

HIV INFECTION

Intent-to-Treat *vs.* On-Treatment
Analyses of Clinical Trial Data:
Experience from a Study of
Pyrimethamine in the Primary
Prophylaxis of Toxoplasmosis in
HIV-Infected Patients, 233

HORMONE REPLACEMENT THERAPY

Design of the Women's Health Initiative
Clinical Trial and Observational
Study, 61

HYDROCHLOROTHIAZIDE

Rationale and Design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial, 370

IMAGE-BASED ENTRY

Feasibility of Keying Data from Screen-Displayed Facsimile Images in an Ongoing Trial: The Collaborative Ocular Melanoma Study, 39

IMPLANTABLE CARDIAC DEFIBRILLATOR

Changes in Sample Size and Length of Follow-up to Maintain Power in The Coronary Artery Bypass Graft (CABG) Patch Trial, 1

INFERTILITY

Design of a PID Evaluation and Clinical Health (PEACH) Study, 499

INTENT-TO-TREAT

Intent-to-Treat *vs.* On-Treatment Analyses of Clinical Trial Data: Experience from a Study of Pyrimethamine in the Primary Prophylaxis of Toxoplasmosis in HIV-Infected Patients, 233
Recurrent Miscarriage (REMIS) Study: How Should Data from Women Who Do Not Become Pregnant Be Handled?, 430

INTERLABORATORY VARIATION

Comparability of Absolute/Percent CD4+ T-Lymphocytes Completed Locally and Centrally, 451

INTERNAL VALIDITY

Threats to the Validity of Clinical Trials Employing Enrichment Strategies for Sample Selection, 178

KEY DATA ENTRY

Feasibility of Keying Data from Screen-Displayed Facsimile Images in an Ongoing Trial: The Collaborative Ocular Melanoma Study, 39

LABORATORY TOXICITY

Laboratory Data in Clinical Trials: A Statistician's Perspective, 167

LINEAR MODELS/REGRESSION

Power and Sample Size Calculation for Studies Involving Linear Regression, 591

LINEAR TRENDS

Comparative Evaluations of Two Models for Estimating Sample Sizes for Tests on Trends Across Repeated Measurements, 188

LOGISTIC REGRESSION

Should We Adjust for Covariates in Nonlinear Regression Analyses of Randomized Trials, 249

LONGITUDINAL MARKERS

An Evaluation of a Measure of the Proportion of the Treatment Effect Explained by a Surrogate Marker, 557

MAGNETIC RESONANCE**ANGIOGRAPHY/IMAGING**

Stroke Prevention Trial in Sickle Cell Anemia, 110

MANAGED CARE

Health Services Clinical Trials: Design, Conduct, and Cost Methodology, 131

META-ANALYSES

Do Certain Countries Produce Only Positive Results? A Systematic Review of Controlled Trials, 159
Should We Adjust for Covariates in Nonlinear Regression Analyses of Randomized Trials, 249

MILLARD METHOD

A Methodology Report of a Randomized Prospective Clinical Trial to Assess Velopharyngeal Function for Speech Following Palatal Surgery, 297

MINORITIES

Successful Techniques for Retention of Study Participants in an Inner-City Population, 546

MONITORING

A Discussion of "Clinical Trials and Effects Monitoring" by Curtis L.

- Meinert, 523, 525, 528, 530, 535, 537, 539
 Clinical Trials and Treatment Effects Monitoring, 515
 Comments on Commentaries of "Clinical Trials and Effects Monitoring" (response), 541
 Data Safety and Monitoring Committees: Accountable to Subjects and Society, 533
 Design of the Women's Health Initiative Clinical Trial and Observational Study, 61
 Guidelines for Quality Assurance in Multicenter Trials: A Position Paper, 477

MULTICENTER TRIALS

- A Design Alternative for Two-Stage, Phase II, Multicenter Cancer Clinical Trials, 440
 Cooperative Studies in Health Services Research in the Department of Veterans Affairs, 134
 Laboratory Data in Clinical Trials: A Statisticians Perspective, 167
 Mailing Strategies and Costs of Recruiting Heavy Smokers in CARET, a Large Chemoprevention Trial, 25
 Statistical Design of REACT (Rapid Early Action for Coronary Treatment), A Multisite Community Trial with Continual Data Collection, 391

MULTISTAGE STUDY DESIGN

- A Design Alternative for Two-Stage, Phase II, Multicenter Cancer Clinical Trials, 440

OMITTED COVARIATES

- Should We Adjust for Covariates in Nonlinear Regression Analyses of Randomized Trials, 249

ON-TREATMENT ANALYSIS

- Intent-to-Treat vs. On-Treatment Analyses of Clinical Trial Data: Experience from a Study of Pyrimethamine in the Primary Prophylaxis of Toxoplasmosis in HIV-Infected Patients, 233

OPHTHALMOLOGY

- The Ischemic Optic Neuropathy Decompression Trial: (IONDT): Design and Methods, 276

OPTIC NEUROPATHY

- The Ischemic Optic Neuropathy Decompression Trial: (IONDT): Design and Methods, 276

OUTCOMES

- Three Years of Experience with Prospective Randomized Effectiveness Studies, 419

PARTIAL FACTORIAL DESIGN

- Design of the Women's Health Initiative Clinical Trial and Observational Study, 61

PEDIATRIC ASTHMA

- Successful Techniques for Retention of Study Participants in an Inner-City Population, 546

PELVIC INFLAMMATORY DISEASE

- Design of a PID Evaluation and Clinical Health (PEACH) Study, 499

POSTMENOPAUSAL HORMONE THERAPY

- Heart and Estrogen/Progestin Replacement Study (HERS): Design, Methods, and Baseline Characteristics, 314

POSTMENOPAUSAL WOMEN

- Design of the Women's Health Initiative Clinical Trial and Observational Study, 61
 Heart and Estrogen/Progestin Replacement Study (HERS): Design, Methods, and Baseline Characteristics, 314

POSTRANDOMIZATION EXCLUSIONS

- Recurrent Miscarriage (REMIS) Study: How Should Data from Women Who Do Not Become Pregnant Be Handled?, 430

POWER

- Changes in Sample Size and Length of Follow-up to Maintain Power in The Coronary Artery Bypass Graft (CABG) Patch Trial, 1
 Comparative Evaluations of Two Models for Estimating Sample Sizes for Tests on Trends Across Repeated Measurements, 188

- Power and Sample Size Calculation for Studies Involving Linear Regression, 591
- Recurrent Miscarriage (REMIS) Study: How Should Data from Women Who Do Not Become Pregnant Be Handled?, 430
- Statistical Design of REACT (Rapid Early Action for Coronary Treatment), A Multisite Community Trial with Continual Data Collection, 391

PRECANCEROUS LESIONS

- Factorial Trial of Three Interventions to Reduce the Progression of Precancerous Gastric Lesions in Shandong, China: Design Issues and Initial Data, 352

PREVENTION

- A Primary Prevention Trial Using Nutritional Doses of Antioxidant Vitamins and Minerals in Cardiovascular Diseases and Cancers in a General Population: The SU.VI.MAX Study-Design, Methods, and Participant Characteristics, 336
- Mailing Strategies and Costs of Recruiting Heavy Smokers in CARET, a Large Chemoprevention Trial, 25
- Prevention Effectiveness: Guide to Decision Analysis and Economic Evaluation* (book review), 212
- Recruitment Strategies in the Women's Health Trial: Feasibility Study in Minority Populations, 461
- The Women's Health Initiative Memory Study (WHIMS): A Trial of the Effect of Estrogen Therapy in Preventing and Slowing the Progress of Dementia, 606
- TRIPOD (TROglitazone in the Prevention of Diabetes): A Randomized, Placebo-controlled Trial of Troglitazone in Women With Prior Gestational Diabetes Mellitus, 217

PUBLISHING

- Do Certain Countries Produce Only Positive Results? A Systematic Review of Controlled Trials, 159
- Publishing Clinical Trials and Dealing with External Comparisons (editorial), 269

QUALITY CONTROL

- Double Data Entry: What Value, What Price?, 15
- Guidelines for Quality Assurance in Multicenter Trials: A Position Paper, 477

RANDOM COEFFICIENTS ANALYSIS

- Statistical Design of REACT (Rapid Early Action for Coronary Treatment), A Multisite Community Trial with Continual Data Collection, 391

RANDOMIZATION

- Three Years of Experience with Prospective Randomized Effectiveness Studies, 419

RATES OF CHANGE

- Comparative Evaluations of Two Models for Estimating Sample Sizes for Tests on Trends Across Repeated Measurements, 188

RECRUITMENT

- Recruitment Strategies in the Women's Health Trial: Feasibility Study in Minority Populations, 461

REFEREE

- Publishing Clinical Trials and Dealing with External Comparisons (editorial), 269

REFERENCE RANGES

- Laboratory Data in Clinical Trials: A Statisticians Perspective, 167

REGRESSION ANALYSIS

- Power and Sample Size Calculation for Studies Involving Linear Regression, 591

REPEATED MEASUREMENTS

- Comparative Evaluations of Two Models for Estimating Sample Sizes for Tests on Trends Across Repeated Measurements, 188

RETENTION

- Successful Techniques for Retention of Study Participants in an Inner-City Population, 546

SAFETY

- Data Safety and Monitoring Committees:
Accountable to Subjects and
Society, 533
- Laboratory Data in Clinical Trials: A
Statistician's Perspective, 167

SAMPLE SIZE

- Changes in Sample Size and Length of
Follow-up to Maintain Power in
The Coronary Artery Bypass Graft
(CABG) Patch Trial, 1
- Comparative Evaluations of Two Models
for Estimating Sample Sizes for
Tests on Trends Across Repeated
Measurements, 188
- Power and Sample Size Calculation for
Studies Involving Linear
Regression, 591
- The Cost-Benefit of a Randomized Trial
to a Health Care Organization,
198

SCIENTIFIC MISCONDUCT

- Guidelines for Quality Assurance in
Multicenter Trials: A Position
Paper, 477

SELENIUM

- Factorial Trial of Three Interventions to
Reduce the Progression of
Precancerous Gastric Lesions in
Shandong, China: Design Issues
and Initial Data, 352

SENSITIVITY

- Sensitivity, Specificity and Vaccine
Efficacy, 571

SICKLE CELL DISEASE

- Stroke Prevention Trial in Sickle Cell
Anemia, 110

SINGLE DATA ENTRY

- Double Data Entry: What Value, What
Price?, 15
- Single or Double Data Entry:
Considerations Based on a
Simple Binomial Model (letter), 56

SMOKING

- Mailing Strategies and Costs of
Recruiting Heavy Smokers in
CARET, a Large
Chemoprevention Trial, 25

SOCIOECONOMIC STATUS

- Recruitment Strategies in the Women's
Health Trial: Feasibility Study in
Minority Populations, 461

SPECIFICITY

- Sensitivity, Specificity and Vaccine
Efficacy, 571

SPEECH OUTCOME

- A Methodology Report of a Randomized
Prospective Clinical Trial to
Assess Velopharyngeal Function
for Speech Following Palatal
Surgery, 297

SPINA METHOD

- A Methodology Report of a Randomized
Prospective Clinical Trial to
Assess Velopharyngeal Function
for Speech Following Palatal
Surgery, 297

STATISTICS. *see also* Specific methods

- Power and Sample Size Calculation for
Studies Involving Linear
Regression, 591
- Statistical Issues in Drug Development*
(book review), 494

STOCHASTIC CURTAILMENT

- Early Stopping of a Clinical Trial When
There is Evidence of No
Treatment Benefit: Protocol B14 of
the National Surgical Adjuvant
Breast and Bowel Project, 577

STOMACH NEOPLASMS

- Factorial Trial of Three Interventions to
Reduce the Progression of
Precancerous Gastric Lesions in
Shandong, China: Design Issues
and Initial Data, 352

STOPPING RULES

- Early Stopping of a Clinical Trial When
There is Evidence of No
Treatment Benefit: Protocol B14 of
the National Surgical Adjuvant
Breast and Bowel Project, 577

STROKE

- Stroke Prevention Trial in Sickle Cell
Anemia, 110

STUDY ORGANIZATION AND MANAGEMENT

- Design of the Women's Health Initiative Clinical Trial and Observational Study, 61
- Cooperative Studies in Health Services Research in Dept. of Veteran Affairs, 134
- Design of a PID Evaluation and Clinical Health (PEACH) Study, 499

SURGERY

- A Methodology Report of a Randomized Prospective Clinical Trial to Assess Velopharyngeal Function for Speech Following Palatal Surgery, 297

SURVEILLANCE STUDIES

- Statistical Design of REACT (Rapid Early Action for Coronary Treatment), A Multisite Community Trial with Continual Data Collection, 391

SURVIVAL ANALYSIS

- Changes in Sample Size and Length of Follow-up to Maintain Power in The Coronary Artery Bypass Graft (CABG) Patch Trial, 1

TAMOXIFEN

- Early Stopping of a Clinical Trial When There is Evidence of No Treatment Benefit: Protocol B14 of the National Surgical Adjuvant Breast and Bowel Project, 577

TEST SIZE

- Recurrent Miscarriage (REMIS) Study: How Should Data from Women Who Do Not Become Pregnant Be Handled?, 430

TIME-DEPENDENT COX MODEL

- An Evaluation of a Measure of the Proportion of the Treatment Effect Explained by a Surrogate Marker, 557

TRACE-ELEMENTS

- A Primary Prevention Trial Using Nutritional Doses of Antioxidant Vitamins and Minerals in Cardiovascular Diseases and Cancers in a General Population: The SU.VI.MAX Study-Design, Methods, and Participant Characteristics, 336

TRANSCRANIAL DOPPLER ULTRASOUND

- Stroke Prevention Trial in Sickle Cell Anemia, 110

TRANSFUSION

- Stroke Prevention Trial in Sickle Cell Anemia, 110

TRIAL MONITORING

- A Discussion of "Clinical Trials and Effects Monitoring" by Curtis L. Meinert, 523, 525, 528, 530, 535, 537, 539
- Clinical Trials and Treatment Effects Monitoring, 515
- Comments on Commentaries of "Clinical Trials and Effects Monitoring" (rejoinder), 541
- Data Safety and Monitoring Committees: Accountable to Subjects and Society, 533
- Design of the Women's Health Initiative Clinical Trial and Observational Study, 61
- Guidelines for Quality Assurance in Multicenter Trials: a Position Paper, 477

TWO-STAGE ANALYTIC METHODS

- Statistical Design of REACT (Rapid Early Action for Coronary Treatment), A Multisite Community Trial with Continual Data Collection, 391

UNBLINDING

- Threats to the Validity of Clinical Trials Employing Enrichment Strategies for Sample Selection, 178

VACCINE EFFICACY

- Sensitivity, Specificity and Vaccine Efficacy, 571

VITAMIN C

- Factorial Trial of Three Interventions to Reduce the Progression of Precancerous Gastric Lesions in Shandong, China: Design Issues and Initial Data, 352

VITAMIN E

Factorial Trial of Three Interventions to Reduce the Progression of Precancerous Gastric Lesions in Shandong, China: Design Issues and Initial Data, 352

VITAMINS

A Primary Prevention Trial Using Nutritional Doses of Antioxidant Vitamins and Minerals in Cardiovascular Diseases and Cancers in a General Population: The SU.VI.MAX Study-Design, Methods, and Participant Characteristics, 336

Factorial Trial of Three Interventions to Reduce the Progression of Precancerous Gastric Lesions in Shandong, China: Design Issues and Initial Data, 352

von LANGENBECK PROCEDURE

A Methodology Report of a Randomized Prospective Clinical Trial to Assess Velopharyngeal Function for Speech Following Palatal Surgery, 297

WITHDRAWAL EFFECT

Threats to the Validity of Clinical Trials Employing Enrichment

Strategies for Sample Selection, 178

WOMEN'S HEALTH

Design of a PID Evaluation and Clinical Health (PEACH) Study, 499

Design of the Women's Health Initiative Clinical Trial and Observational Study, 61

Early Stopping of a Clinical Trial When There is Evidence of No Treatment Benefit: Protocol B14 of the National Surgical Adjuvant Breast and Bowel Project, 577

Heart and Estrogen/Progestin Replacement Study (HERS): Design, Methods, and Baseline Characteristics, 314

Intent-to-Treat vs. On-Treatment Analyses of Clinical Trial Data: Experience from a Study of Pyrimethamine in the Primary Prophylaxis of Toxoplasmosis in HIV-Infected Patients, 233

Recruitment Strategies in the Women's Health Trial: Feasibility Study in Minority Populations, 461

The Women's Health Initiative Memory Study (WHIMS): A Trial of the Effect of Estrogen Therapy in Preventing and Slowing the Progress of Dementia, 606